Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Immune Design, CRI, Ludwig Institute for Cancer Research deal

The institutes will conduct clinical trials to evaluate Immune Design's glucopyranosyl lipid A (GLA) adjuvant and LV305 lentivector-based

Read the full 185 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE